• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.41%

    ProFunds Pharmaceuticals UltraSector Svc (PHPSX)

    20.01 Up 0.09(0.45%) Oct 8

    Profile as of Sep 29, 2015Get Profile for:
    ProFunds Pharmaceuticals UltraSector Svc
    Profunds3435 Stelzler RdColumbus, OH 43219
    Phone: 888-776-3637
    Fund Overview 
    Category:Trading-Leveraged Equity
    Fund Family:ProFunds
    Net Assets:16.20M
    Year-to-Date Return:-7.08%
    Morningstar Rating:2 stars
    Fund Inception Date:Jun 28, 2000
    Morningstar Style Box 
    Trading-Leveraged Equity
    [View Category Definition]
    View Top Trading-Leveraged Equity Funds
    About the Morningstar Style Box
    Management Information 
    Michael Neches
    Lead Manager since Oct 1, 2013
    Michael Neches: ProShare Advisors: Senior Portfolio Manager since November 2010 and Portfolio Manager from January 2010 through October 2010. ProShares Capital Management LLC: Senior Portfolio Manager from June 2012 through September 2013.
    Investment Information 
    Min Initial Investment:15,000
    Min Initial Investment, IRA:15,000
    Min Initial Investment, AIP:15,000
    Min Subsequent Investment:N/A
    Min Subsequent Investment, IRA:N/A
    Min Subsequent Investment, AIP:N/A
    PHPSX can be purchased from 47 brokerages.

    Fund Summary 
    The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. PharmaceuticalsSM Index. The fund invests in securities and derivatives that the adviser believes, in combination, should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the pharmaceuticals sector of the U.S. equity market. The fund is non-diversified.

    Fund Operations 
    Last Dividend : 0.00
    Last Cap Gain (Dec 14, 2014) : 0.00
    Annual Holdings Turnover (Oct 6, 2015) : 92.00%
    Average for Category:247.22%
    Fees & Expenses 
    ExpensePHPSXCategory Avg
    Annual Report Expense Ratio (net):2.74%2.03%
    Prospectus Net Expense Ratio:2.74%N/A
    Prospectus Gross Expense Ratio:2.74%N/A
    Max 12b1 Fee:1.00%N/A
    Max Front End Sales Load:N/A4.75%
    Max Deferred Sales Load: N/A1.00%
    3 Yr Expense Projection*:850701
    5 Yr Expense Projection*:1,4501,166
    10 Yr Expense Projection*:3,0702,448
    * Per $10,000 invested